The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin | Cardiovascular Diabetology | Full Text
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus - Chen - 2015 - Clinical and Experimental Pharmacology and Physiology - Wiley Online Library
Mechanism of Action of GLP-1RAs and DPP-4 inhibitors. DPP-4 inhibitors... | Download Scientific Diagram
Saxagliptin: Uses, Interactions, Mechanism of Action | DrugBank Online
Impact of baseline characteristics on glycemic effects of add‐on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus - Fang -
dpp-4_inhibitors [TUSOM | Pharmwiki]
Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1α/CXCR4, and Kim-1/STAT3/HIF-1α/VEGF/eNOS pathways - ScienceDirect
ONGLYZA® (saxagliptin) | Mechanism of Action | Onglyza-HCP.com
Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor | SpringerLink
Saxagliptin - Wikipedia
Supplemental Materials for Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial - Diabetes Research and Clinical Practice
Saxagliptin - Wikipedia
Beneficial effects of saxagliptin on PG (A), IRI (B), CPR (C), and... | Download Scientific Diagram